



BRITISH SOCIETY FOR
**ANTIMICROBIAL
CHEMOTHERAPY**

2018

NATIONAL OPAT CONFERENCE

13 - 14 DECEMBER 2018
THE ICC, BIRMINGHAM



DELEGATE BROCHURE

 **#OPAT18**

13 DECEMBER 2018**0930 Welcome and Opening Remarks**

Mr Mark Gilchrist, Consultant Pharmacist, Infectious Diseases, Imperial College Healthcare NHS Trust, London

SESSION ONE: CAN I TELL YOU A STORY?

Chair, Dr Sanjay Patel, Consultant in Paediatric Infectious Diseases and Immunology, Southampton Children's Hospital

0940 My OPAT journey - a younger person's perspective, Question and Answer session

Mr Thomas Mallet, Young person, Southampton Children's Hospital OPAT service patient in 2017

SESSION TWO: OPAT CHALLENGES IN SPECIFIC CONDITIONS

Chair: Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine & Antimicrobial Management Team Lead NHS GGC, Queen Elizabeth University Hospital, Glasgow

1015 OPAT via telemedicine (Presentation via Webcam)

Dr Paul Ingram - PathWest, Royal Perth Hospital, Fiona Stanley Hospital, Western Australia

1030 Defining the positive outcome - OPAT in palliative care

Dr Eoghan de Barra, Consultant in Infectious Diseases and Internal Medicine, Beaumont Hospital/Royal College of Surgeons in Ireland

1045 Managing Staphylococcal Bacteraemias

Sanjita Brito-Mutunayagam, Junior doctor in Infectious Diseases Royal Infectious Diseases Unit, NHS Lothian.

1100 The challenge of orthopaedic infections in the post OVIVA era

Dr Bridget Atkins, Consultant in Microbiology and Infectious Diseases, Oxford University Hospitals NHS FT

1115 Q&A

1130 REFRESHMENTS AND NETWORKING

SESSION THREE: DELIVERING SAFER OPAT

Chair: Dr Eoghan de Barra, Consultant in Infectious Diseases and Internal Medicine, Beaumont Hospital/Royal College of Surgeons in Ireland

1200 Good Practice Recommendations - the key learning points

Dr Ann Chapman, Consultant Infectious Disease and General Medicine, NHS Lanarkshire

1215 Using OPAT to drive paediatric stewardship

Dr Sanjay Patel, Consultant in Paediatric Infectious Diseases and Immunology, Southampton Children's Hospital & Miss Emily Tanner, Medical Student, University of Southampton

1235 Beyond the OPAT MDT: hazards and opportunities

Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine & Antimicrobial Management Team Lead NHS GGC, Queen Elizabeth University Hospital, Glasgow

DEBATE: OPAT COMPETENCIES - NEEDED OR NOT?

Chair: Dr Eoghan de Barra, Consultant in Infectious Diseases and Internal Medicine, Beaumont Hospital/Royal College of Surgeons in Ireland

1255 Speaking in favour

Dr Sue Snape, Consultant in Microbiology and Infectious Diseases, Nottingham University Hospitals NHS

1305 Speaking against

Dr Sarah Logan, Consultant In infectious disease and General medicine, Hospital for Tropical Diseases at UCLH

SESSION FOUR:

Supported by Correvio

1315 Dalbavancin: Real world experience in complex and underserved patient groups

1400 LUNCH AND POSTER VIEWING

SESSION FIVE: DRUGS & DEVICES

Chair: Mr Mark Gilchrist, Consultant Pharmacist, Infectious Diseases, Imperial College Healthcare NHS Trust, London

1500 Outpatient management of complex oral antibiotic regimens

Mrs Julie Statham, Principal Pharmacist for Infection, South Warwickshire NHS Foundation Trust

1515 ECG directed PICC line insertion

Mrs Elizabeth Wilson, OPAT Lead Nurse, Wythenshawe Hospital, Manchester University Foundation NHS Trust

1530 Vascular health management in children

Miss Ruth Cantwell, Alder Hey Hospital

1545 Evaluating the safety of antibiotic administration using elastomeric devices in children managed within a tertiary paediatric OPAT service

Mrs Jacqueline Gray, Paediatric Infectious Diseases & OPAT CNS, University Hospital Southampton

1600 A comparison of bolus versus infusion administration of ceftriaxone in patients under OPAT

Miss Lucille Mclean, Medical Student, University of Cambridge

1615 REFRESHMENTS AND NETWORKING

SESSION SIX: LESSONS AND DILEMMAS FROM THE REGIONS

Chair: Gavin Barlow, ID Consultant, Hull & East Yorkshire Hospitals NHS Trust

1645 Setting up an in house elastomeric device service for OPAT

Dr Sue Snape, Consultant in Microbiology and Infectious Diseases, Nottingham University Hospitals NHS Trust

1700 Role of OPAT in haemodialysis

Dr Carolyn Hemsley, Microbiology and Infectious Disease Consultant, Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London

1715 Vascular graft infection and OPAT

Dr Fiona Andrewartha, OPAT Consultant, Nottingham

1730 Tubo-ovarian abscess and OPAT

Dr James Hatcher, Consultant in Infectious Diseases and Medical Microbiology, Imperial College Healthcare NHS Trust

1745 Nurse led management of SSTIs

Ms Claire Vallance, Lead Clinical Nurse Specialist OPAT, NHS Greater Glasgow & Clyde

SESSION SEVEN: NATIONAL DISCUSSION FORUM

Chair: Gavin Barlow, ID Consultant, Hull & East Yorkshire Hospitals NHS Trust

1800 Facilitated discussion addressing issues raised by delegates

Panel comprising:

Mr Mark Gilchrist, Consultant Pharmacist, Infectious Diseases, Imperial College Healthcare NHS Trust, London

Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine & Antimicrobial Management Team Lead NHS GGC, Queen Elizabeth University Hospital, Glasgow

Dr Sanjay Patel, Consultant in Paediatric Infectious Diseases and Immunology, Southampton Children's Hospital

Mrs Liz Wilson, OPAT Lead Nurse, Wythenshawe Hospital, Manchester University Foundation NHS Trust

Dr Ann Chapman, Consultant Infectious Disease and General Medicine, NHS Lanarkshire

1845 Welcome drinks, networking and poster presentations**14 DECEMBER 2018****0730** Breakfast refreshments

SESSION EIGHT: INTERACTIVE CLINICAL CASE STUDIES

Chair: Dr Carolyn Hemsley, Microbiology and Infectious Disease Consultant, Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London

0800 Case study 1: Ubi pus ibi evaquat

Dr Chris Lynch, Microbiology Registrar, Sheffield Teaching Hospitals

0815 Case study 2: Double trouble

Dr Chris Lynch, Microbiology Registrar, Sheffield Teaching Hospitals

0830 Case study 3: Endocarditis, haemodialysis and OPAT – treatment challenges

Dr Hector Maxwell-Scott, Infectious Diseases / Microbiology Registrar, Guys & St Thomas' Hospital, London

0845 Case study 4: Prolonged OPAT for Mycobacterium abscessus

Dr Anna Goodman, Guys & St Thomas' Hospital, London

0900 Panel discussion

SESSION NINE:

Supported by Baxter

0915 Defining Value in S-OPAT

Mrs Arthi Squires, Evolving Health Manager, Baxter Healthcare Ltd

1000 REFRESHMENTS AND NETWORKING

SESSION TEN: KEYNOTE LECTURE

Chair: Mr Tim Hills, Lead Pharmacist, Antimicrobials and Infection Control, Nottingham University Hospitals NHS Trust

1100 Role of extended dosing interval antimicrobials in OPAT

Dr Urania Rappo, Director, Clinical Development (Anti-Infectives), Allergan

1130 Q&A

SESSION ELEVEN: INVITED PAPERS

Chair: Dr Ann Chapman, Consultant Infectious Disease and General Medicine, NHS Lanarkshire

1145 Colour coded classification of OPAT patients as an alternative model of care

Mrs Julie Statham, Principal Pharmacist for Infection, South Warwickshire NHS Foundation Trust

1155 Developing a Risk Prediction Model for 30-Day Unplanned Hospitalisation in Patients Receiving Outpatient Parenteral Antimicrobial Therapy.

Dr Chris Oyewole Durojaiye, Consultant Physician in Infectious Diseases and Tropical Medicine at Sheffield Teaching Hospitals NHS Foundation Trust

1205 Identifying risk factors for non-completion of OPAT course to enable intervention before and during home treatment

Dr Ian Miskin, Infectious Diseases Consultant, Clalit Health Services, Jerusalem District, Israel

1215 Using NORS data to optimise duration of antibiotic therapy in OPAT

Dr John Williams, Consultant ID Physician, The James Cook University Hospital, Middlesbrough, UK

1225 A systematic review of Human Factors identified from Outpatient Parenteral Antimicrobial Therapy research using the SEIPS 2.0 model

Mrs Sara Jo Bugeja, PhD student, Robert Gordon University

1235 Discussion

SESSION TWELVE: INFORMING THE FUTURE AGENDA

Chair: Dr Andrew Seaton, Consultant in Infectious Diseases and General Medicine & Antimicrobial Management Team Lead NHS GGC, Queen Elizabeth University Hospital, Glasgow

1245 Measuring practice and outcomes - Registry outputs and what they mean

Mr Mark Gilchrist, Consultant Pharmacist, Infectious Diseases, Imperial College Healthcare NHS Trust, London

1300 UK Drug Stability Testing Programme - outputs and future aspirations

Dr Conor Jamieson, Pharmacy Team Leader – Antimicrobial Therapy, Sandwell and West Birmingham NHS Trust

1315 OPAT 2019 and beyond

Mr Mark Gilchrist, Consultant Pharmacist, Infectious Diseases, Imperial College Healthcare NHS Trust, London

1330 Close
